NCT05873634招募中不适用
HeartShare Deep Phenotyping Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,000
- 试验地点
- 8
- 主要终点
- Number of participants with Heart Failure with Preserved Ejection Fraction (HFpEF)
研究概览
简要总结
HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes to help develop more personalized treatments for patients, with the hope that this will improve the lives of heart failure patients. To do this, HeartShare is bringing together a large amount of data (including images, such as heart ultrasounds and MRIs and molecular data from the blood, such as genetics) from previously conducted studies and electronic health records, and is gathering new data through participants enrolled in the HeartShare Deep Phenotyping Study.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •HF Inclusion Criteria (HeartShare Registry)
- •Age ≥30 years.
- •Prior diagnosis of HF in the EHR (any left ventricular ejection fraction).
- •Non-HF Group Inclusion Criteria (HeartShare Registry)
- •Age ≥30 years.
- •No known prior diagnosis of HF or use of loop diuretics.
- •No known prior history of BNP >100 pg/ml or NTproBNP >300 pg/ml, if prior laboratory tests are available in the EHR.
- •HFpEF Inclusion Criteria (HeartShare Deep Phenotyping Cohort)
- •Age ≥30 years.
- •Left ventricular ejection fraction ≥50% measured by echocardiography.
- •Definition of HFpEF: signs and symptoms of HF, NYHA functional class II-IV, and at least one of the following:
- •Elevated BNP (≥75 pg/ml in sinus rhythm or ≥225 pg/ml in atrial fibrillation/flutter) or NTproBNP (≥225 pg/ml in sinus rhythm or ≥675 in atrial fibrillation/flutter) at baseline. Choice of BNP or NTproBNP is based on availability at each clinical center.
- •Prior HF hospitalization (primary reason for the hospitalization is HF with elevated natriuretic peptide levels [using the thresholds listed above], requiring IV diuresis for HF, or pulmonary edema or pulmonary vascular congestion on chest radiography).
- •Elevated pulmonary capillary wedge pressure (PCWP) at rest (≥15 mmHg) or during exercise (≥25 mmHg for supine exercise or PCWP/cardiac output ratio ≥2 mmHg/L/min for upright exercise).
- •Elevated H2FPEF score26 (≥5) or HFA-PEFF27 score (≥5).
- •Non-HFpEF Group Inclusion Criteria (HeartShare Deep Phenotyping Cohort)
- •Age ≥30 years.
- •Left ventricular ejection fraction ≥50% measured by echocardiography.
- •No known prior diagnosis of HF or use of diuretics for fluid management.
- •No known prior history of BNP ≥75 pg/ml or NTproBNP ≥225 pg/ml, if prior laboratory tests are available in the EHR.
- •BNP <75 pg/ml or NTproBNP <225 pg/ml at the time of screening. Choice of BNP or NTproBNP is based on availability at each clinical center.
排除标准
- •Exclusion Criteria (HeartShare Registry) The following exclusion criteria apply to both HF and non-HF group participants, unless otherwise indicated.
- •For non-HF group: any prior known left ventricular ejection fraction <50%.
- •Prior history of solid organ transplantation.
- •Prior history of mechanical circulatory support.
- •Prior history of non-cardiac cirrhosis.
- •Inability to provide written consent to the study.
- •Exclusion Criteria (HeartShare Deep Phenotyping Cohort) The following exclusion criteria apply to both HFpEF and non-HFpEF group participants, unless otherwise indicated.
- •Life expectancy estimated to be < 1 year.
- •Primary cardiomyopathy (including amyloid, hypertrophic cardiomyopathy, cardiac sarcoidosis, hemochromatosis, or other infiltrative cardiomyopathies) or pulmonary arterial hypertension (WHO Group I, III, or IV pulmonary hypertension).
- •Any prior known left ventricular ejection fraction <40%, except if this occurred only in the setting of an acute tachycardia episode (e.g., acute atrial fibrillation).
- •Clinically significant valvular heart disease defined as:
- •Moderate to greater aortic stenosis, pulmonic stenosis, or tricuspid stenosis.
- •Any mitral stenosis.
- •Moderate or greater aortic regurgitation.
- •Greater than moderate mitral regurgitation.
- •Any planned cardiac surgery or cardiac intervention in the next 3 months.
- •Alternative primary reason for symptoms of shortness of breath and exercise intolerance in HFpEF participants in the opinion of the enrolling investigator.
- •Cardiac surgery, acute coronary syndrome, percutaneous coronary intervention, stroke, transient ischemic attack, or carotid intervention in the preceding 6 months prior to enrollment.
- •Known symptomatic epicardial coronary artery disease that is not revascularized.
- •Any non-elective hospitalization in the preceding 2 weeks.
- •Prior history of solid organ transplantation.
- •Prior history of chronic infection (HIV, hepatitis C, hepatitis B, tuberculosis) unless treated and not clinically active in the opinion of the enrolling investigator.
- •Prior history of mechanical circulatory support.
- •Prior history of non-cardiac cirrhosis.
- •Estimated GFR <20 ml/min/1.73m2 or currently on dialysis.
- •Any condition that may preclude participation or adherence to the study protocol, in the opinion of the enrolling investigator.
- •Inability to provide written consent to the study.
- •Current acute decompensated heart failure.
- •Currently pregnant.
研究组 & 干预措施
HFpEF
Participants with HFpEF
Non-HFpEF
Participants without HFpEF
结局指标
主要结局
Number of participants with Heart Failure with Preserved Ejection Fraction (HFpEF)
时间窗: Up to 5 years
次要结局
未报告次要终点
研究者
Sanjiv Shah
Stone Endowed Professor of Medicine, Director of Research, Bluhm Cardiovascular Institute, Principal Investigator, HeartShare Data Translation Center
Northwestern University
研究点 (8)
Loading locations...
相似试验
进行中（未招募）
不适用
PACIFIC-PRESERVED : PhenomApping, ClassIFication, and Innovation for Cardiac Dysfunction - HF With PRESERVED LVEF StudyHeart Failure With Preserved Ejection FractionHeart FailureNCT04189029Assistance Publique - Hôpitaux de Paris175
Enrolling By Invitation
不适用
Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)Heart FailureNCT06280820National Heart, Lung, and Blood Institute (NHLBI)2,000
已完成
不适用
Cohort Study of Chronic Heart FailureAnalyze Etiology, Comorbidities, Clinical CharacteristicsNCT06092658Xiang Xie20,000
终止
不适用
Evaluating Mobile Health Tool Use for Capturing Patient-centered Outcomes Measures in HF PatientsHeart FailureNCT04191356Biofourmis Singapore Pte Ltd.67
招募中
不适用
Heart Failure Precision Medicine StudyHeart FailureNCT04196842University of California, Davis100